MPR Weekly Dose Podcast #259 — ACIP Hep B Recommendation; Retatrutide Shows Promise; Omisirge Approved; Counterfeit Ozempic Seized; Gene Tx Approved for Wiskott-Aldrich Syndrome
ACIP votes to change hep B vaccination for infants; positive results for retatrutide; Omisirge approved; counterfeit Ozempic seized by FDA; gene therapy approved for Wiskott-Aldrich syndrome.
12 Joulu 202514min
MPR Weekly Dose Podcast #258 — Jaypirca Gains Expanded Approval; Allograft to Restore Nerve Function; Baxdrostat Gets Priority Review; Stargardt Tx Shows Promise; Edema Autoinjector Accepted for Review
Jaypirca gains expanded approval; allograft approved to restore peripheral nerve function; baxdrostat to be reviewed as an add-on treatment for hypertension; treatment for a genetic eye disorder that ...
5 Joulu 202511min
MPR Weekly Dose Podcast #257 — Tonmya Available; Elevidys Safety Warning; Mitapivat SCD Trial Results; Redemplo Approved for FCS; Hyrnuo Granted Accelerated Approval
Tonmya now available for fibromyalgia; safety warnings for DMD treatment; mitapivat shows mixed results in sickle cell disease trial; Redemplo approved for familial chylomicronemia syndrome; Hyrnuo ap...
21 Marras 202514min
MPR Weekly Dose Podcast #256 — HRT Label Changes; Calypta Approved for MDD; Darzalex Faspro Indication Expanded; MS Tx Potential; Simplified HIV Regimen
The FDA requests boxed warnings be removed from HRT product labels; Caplyta approved for MDD; Darzalex Faspro gains new indication; investigational MS treatment looks promising; trial investigates sim...
14 Marras 202513min
MPR News Weekly Dose #255 — Fluoride Supplements Restricted; AAP Leucovorin Statement; At-Home Ultrasound; Kygevvi Approved; Gazyva Lupus Trial Results
FDA restrict the sale of unapproved fluoride products; the AAP statement on leucovorin in ASD; at-home prenatal ultrasound; Kygevvi approved; Gazyva reduces SLE disease activity.
7 Marras 202513min
MPR Weekly Dose #254 — Tranexamic Acid Label Change; New Tezspire Approval; Psychedelic Gains Breakthrough; Oral Semaglutide for MACE Reduction; Gazyva Approved for Lupus
Label changes for tranexamic acid; new approval for Tezspire; psychedelic gains Breakthrough Tx for depression; oral semaglutide approved to reduce MACE risk in T2DM; Gazyva approved for lupus.
24 Loka 202515min
MPR Weekly Dose Podcast #253 — Bipolar I Treatment; Blood-Based Test for Alzheimer Disease; UC Tx Approved for Pediatrics; Rinvoq Expanded; Oral Glucagon-Like Peptide-1
New treatment approved for Bipolar I disorder; IBD treatments gain expanded approval; blood-based test for early detection of Alzheimer disease; and an oral glucagon-like peptide-1 treatment continues...
17 Loka 202511min
MPR Weekly Dose Podcast #252 — CDC Approves New Immunization Sched; Novel Furosemide Delivery Device; New IPF Treatment Approved; Libtayo approved for CSCC; Breakthrough Therapy for influenza
CDC approves new immunization schedule; new treatments approved for edema, idiopathic pulmonary fibrosis, and high risk cutaneous squamous cell carcinoma; and the FDA grants Breakthrough therapy desig...
10 Loka 202513min
